US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

163.59

+11.047.24%

Volume:213.21K

Turnover:34.33M

Market Cap:797.42M

PE:- -

High:164.30

Open:155.28

Low:155.21

Close:152.55

52wk High:176.44

52wk Low:32.55

Shares:4.87M

Float Shares:4.87M

Volume Ratio:4.37

T/O Rate:4.37%

Dividend:0.43

Dividend Rate:0.26%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Sector Update: Health Care Stocks Retreat Tuesday Afternoon

MT Newswires Live

Should Ryman’s $1b Recap and Australian Funding Shift Require Action From Ryman Healthcare (NZSE:RYM) Investors?

Simply Wall St.

BofA Survey: Healthcare Tops European Fund Managers' Overweight Sectors

Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference

China Healthcare Sector's Out-Licensing Set to Stay Strong -- Market Talk

Yestar Healthcare Explores Expansion Into Advanced Materials; Shares Fall 5%

MT Newswires Live

Hygeia Healthcare's Share Buyback Could Boost Sentiment -- Market Talk

Sigma Healthcare May Benefit From UK's Pharmacy Store Regulation, Says Jefferies

MT Newswires Live

What Prestige Consumer Healthcare (PBH)'s Buybacks and Brandes Stake Mean for Cash-Flow-Focused Shareholders

Simply Wall St.

Perennial Healthcare City Launched Adjacent to Chongqing East HSR Station, Western China's Largest HSR Hub

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Press Release: Firstsource announces leadership changes to accelerate growth across Healthcare Payer and Provider businesses

Healthcare Realty Trust (HR): Valuation Check After Cantor Backs Strategy and $1 Billion Asset Sale Plan

Simply Wall St.

SCWorx Continues to Expand Healthcare Data Management Network with New Partnership

Sector Update: Health Care Stocks Advance Pre-Bell Monday

MT Newswires Live

Hygeia Healthcare Eyes 300 Million Share Buyback

MT Newswires Live

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

Reassessing Molina Healthcare (MOH): Is the Recent Share Price Rebound Enough to Shift Its Valuation?

Simply Wall St.

Manulife and Bupa Sign MoU for Strategic Collaboration in Hong Kong to Create a More Robust, Integrated Healthcare Network Offering Customers Greater Access and Choice

Two Chinese Healthcare Firms Eye Hong Kong IPOs Amid Biopharma Fundraising Boom

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LABU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":163.59,"timestamp":1766156834759,"preClose":152.55,"halted":0,"volume":213207,"delay":0,"floatShares":4874486,"shares":4874486,"eps":0,"marketStatus":"Trading","change":11.04,"latestTime":"12-19 10:07:17 EST","open":155.28,"high":164.3,"low":155.21,"amount":34327149.97902,"amplitude":0.059587,"askPrice":164,"askSize":700,"bidPrice":163.55,"bidSize":200,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766178000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":152.55,"sharesOutstanding":4874486,"nav":155.953,"aum":760189675.99,"dividendRate":0.002611,"bidAskSpread":0.002334,"preHourTrading":{"tag":"盘前","latestPrice":154.9493,"preClose":152.55,"latestTime":"09:23 EST","volume":2158,"amount":333483.1851,"timestamp":1766154211777},"postHourTrading":{"tag":"盘后","latestPrice":152,"preClose":152.55,"latestTime":"19:59 EST","volume":2119,"amount":322472.5255,"timestamp":1766105971851},"volumeRatio":4.37374,"impliedVol":0.8415,"impliedVolPercentile":0.348},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":4874486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.37374,"shares":4874486,"dividePrice":0.4271,"high":164.3,"amplitude":0.059587,"preClose":152.55,"low":155.21,"week52Low":32.55,"pbRate":"--","week52High":176.44,"institutionHeld":0,"latestPrice":163.59,"committee":-0.428571,"eps":0,"divideRate":0.002611,"volume":213207,"delay":0,"ttmEps":0,"open":155.28,"prevYearClose":90,"prevWeekClose":164.81,"prevMonthClose":166.65,"prevQuarterClose":93.61,"fiveDayClose":164.81,"twentyDayClose":132.83,"sixtyDayClose":82.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592293104","title":"Sector Update: Health Care Stocks Retreat Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2592293104","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592293104?lang=en_us&edition=fundamental","pubTime":"2025-12-17 02:46","pubTimestamp":1765910802,"startTime":"0","endTime":"0","summary":"Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index falling 1.7% and the State Street Health Care Select Sector SPDR ETF  dropping 1.9%.The iShares Biotechnology ETF  retreated 1.1%.In corporate news, Pfizer  issued an earnings outlook for 2026 below market expectations and said its COVID-19 sales are expected to decline during the year on an annual basis, while the pharmaceutical giant revised its revenue guidance for 2025. Its shares dropped 5.1%.Abivax  stock fell 5.8% after the company reported a wider Q3 loss.Medtronic  shares fell 1.2% after Baird cut the company's price target to $103 from $109, and kept its neutral rating.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0234572021.USD","LU0058720904.USD","LU0211331839.USD","LU0432979614.USD","LU0496365809.HKD","LU0265550359.USD","XBI","LU1894683348.USD","LU2089984988.USD","LU0306806265.USD","LU0314106906.USD","BK4550","BK7095","SG9999001176.SGD","SG9999002232.USD","IE00BVYPNV92.GBP","LU0985481810.HKD","IE00BBT3K403.USD","BK4585","BK4534","IE00BDGV0183.EUR","IE00BLSP4452.SGD","LU0208291251.USD","BK4581","LABU","LU0321505439.SGD","LU1983299246.USD","IE00BLSP4239.USD","LU2028103732.USD","LU1506573853.SGD","LU0265550946.USD","IE00B19Z3B42.SGD","BK4592","LU1989771016.USD","LU2023251221.USD","LU1023059063.AUD","LU1061106388.HKD","IE00B19Z3581.USD","LU2111349929.HKD","IE00BQXX3D17.EUR","LU0306807586.USD","IE00BQXX3C00.GBP","IE00BVYPNW00.USD","LU1066051498.USD","LU1116320901.HKD","LU0225284248.USD","LU1291159041.SGD","LU0158827948.USD","BK4588","LU0868494617.USD","LU0225771236.USD","BK4566","SG9999011175.SGD","LU0211326755.USD","IE000M9KFDE8.USD","LU1066053197.SGD","LU1883839398.USD","IE00BFXG1179.USD","LU0122379950.USD","LU1894683264.USD","IE00B42XCP33.USD","LU2112291526.USD","LU1116320737.USD","LU0321505868.SGD","LU2089283258.USD","LU0070302665.USD","LU0289739699.SGD","LU1989764748.USD","LU1244550494.USD","LU2468319806.SGD","LU2089284900.SGD","LU2271345857.HKD","SG9999001176.USD","BK4599","LU0976567544.SGD","PFE","LU1244550221.USD","LU0158827781.USD","LU0320765489.SGD","SGXZ57979304.SGD","BK4139","LU1571399168.USD","LU1244550577.SGD","SG9999003800.SGD","LU0162691827.USD","BK4082","LU0211326839.USD","LU0456855351.SGD","BK4533","LU0170899867.USD","BK4007","BK4568","IE0002270589.USD","SG9999013999.USD","XLV","IE00BQXX3F31.USD","SG9999002224.SGD","LU1057294990.SGD","IBB","LU1989764664.SGD","IE00BGHQF631.EUR","IE00B3PB1722.GBP","LU0072461881.USD","IE00B3T34201.USD"],"gpt_icon":1},{"id":"2592953759","title":"Should Ryman’s $1b Recap and Australian Funding Shift Require Action From Ryman Healthcare (NZSE:RYM) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592953759","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592953759?lang=en_us&edition=fundamental","pubTime":"2025-12-16 23:17","pubTimestamp":1765898245,"startTime":"0","endTime":"0","summary":"Ryman Healthcare has recently completed a financial overhaul under new CEO Naomi James, including a very large capital raising of about $1.00 billion and a reset of its capital structure, while Australian aged-care reforms have improved funding arrangements for operators.\nA key shift is that Australian rules now allow providers like Ryman to retain a portion of new refundable accommodation deposits, creating a structurally more supportive revenue model for its care operations.\nWe’ll now...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/should-rymans-1b-recap-and-australian-funding-shift-require","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/should-rymans-1b-recap-and-australian-funding-shift-require","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4581","BK4585","RYM","XBI","LABU","RYM.NZ","XLV","XJO.AU","BK8050","ISBC","XKO.AU","XAO.AU","BK4211","BK4588","BK4152"],"gpt_icon":0},{"id":"1107866208","title":"BofA Survey: Healthcare Tops European Fund Managers' Overweight Sectors","url":"https://stock-news.laohu8.com/highlight/detail?id=1107866208","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107866208?lang=en_us&edition=fundamental","pubTime":"2025-12-16 23:12","pubTimestamp":1765897931,"startTime":"0","endTime":"0","summary":"According to Bank of America's December survey of European fund managers, healthcare remains the most overweight sector among European portfolio managers. However, financials continue to be a favored...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","XBI","BK4581","159760","XLV","LABU"],"gpt_icon":0},{"id":"2591981666","title":"Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2591981666","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591981666?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:00","pubTimestamp":1765886400,"startTime":"0","endTime":"0","summary":"CHASKA, Minn., Dec.  16, 2025   -- Lifecore Biomedical, Inc.  , a fully integrated contract development and manufacturing organization , today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California. Details regarding Lifecore’s participation are as follows: 44th Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in 1-on-1 meetings Conference Dates: January 12-15, 2026Location: San Francisco, California About Lifecore Biomedical Lifecore Biomedical, Inc.  is a fully integrated contract development and manufacturing organization  that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufac","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/16/3206095/23089/en/Lifecore-Biomedical-to-Participate-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","LU0557290698.USD","BK4137","LU1989772923.USD","BK4534","LU0098860793.USD","LU0225283273.USD","HCSG","LU1720051017.SGD","LABU","LU2111349929.HKD","LU0006306889.USD","LU0795875086.SGD","LU0912757837.SGD","LU1720051108.HKD","LU0234570918.USD","BK4139","LU2028103732.USD","LU0314104364.USD","LU2347655156.SGD","LU1732800096.USD","LU1989772840.SGD","LU0106261372.USD","LU0029874061.USD","XLV","LU1791710400.SGD","CDMO","BK4585","BK4504","BK4588","LU1162221912.USD","IE00BZ1G4Q59.USD","LU2089283258.USD","LU2089284900.SGD","LU0528227936.USD","LU1363072403.SGD","LU0158827781.USD","LU1244550221.USD","CFO","BK4581","LU0106831901.USD","LU2271345857.HKD","XBI","BK4121","LU0795875169.SGD","LFCR","LU0971096721.USD","LU0128526141.USD","LU0158827948.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2591600991","title":"China Healthcare Sector's Out-Licensing Set to Stay Strong -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2591600991","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591600991?lang=en_us&edition=fundamental","pubTime":"2025-12-16 17:31","pubTimestamp":1765877460,"startTime":"0","endTime":"0","summary":"0931 GMT - Innovation in China's healthcare sector should remain a key theme for 2026 despite recent underperformance, which Nomura analyst Jialin Zhang attributes to profit-taking. Zhang expects out-licensing activity to stay strong, supported by continued research and development investment, sustained cost and efficiency advantages over overseas peers, and fewer geopolitical hurdles following the recent U.S.-China trade truce. Zhang says it is critical to monitor the clinical progress of out-licensed assets next year, including data readouts and the speed of clinical trials. RNAi-based therapies could drive the next wave of out-licensing after weight-loss and oncology treatments, he adds, with IPO filings from RNAi companies potentially drawing further investor interest to the segment. Nomura tips Hengrui, Innovent, BeOne Medicines, Wuxi XDC and Mindray as its sector picks. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XBI","LU0029874061.USD","BK4137","BK4585","HCSG","LABU","LU0128526141.USD","XLV","BK4581"],"gpt_icon":0},{"id":"2591606169","title":"Yestar Healthcare Explores Expansion Into Advanced Materials; Shares Fall 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591606169","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591606169?lang=en_us&edition=fundamental","pubTime":"2025-12-16 15:07","pubTimestamp":1765868844,"startTime":"0","endTime":"0","summary":"Yestar Healthcare  said it is exploring a potential expansion into the advanced materials industry, according to a Monday Hong Kong bourse filing.Shares of the healthcare consumables and equipment maker were down nearly 5% in Tuesday afternoon trading.The company said it is assessing potential investments in coating production lines, research and development equipment, and related patents, with an initial focus on applications in the oil and gas, hydrogen, and new energy sectors.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4157","IE0031619046.USD","LU0128526141.USD","IE00B7SZL793.SGD","LU0029874061.USD","BK1222","BK4581","BK4585","02393","XBI","LABU","BK4137","XLV","IE00B19Z4B17.USD","IE00B66KJ199.SGD","LU0757428866.USD","AEIS","LU1815336091.USD","HCSG","BK4588"],"gpt_icon":0},{"id":"2591160659","title":"Hygeia Healthcare's Share Buyback Could Boost Sentiment -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2591160659","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591160659?lang=en_us&edition=fundamental","pubTime":"2025-12-16 14:59","pubTimestamp":1765868340,"startTime":"0","endTime":"0","summary":"0659 GMT - Hygeia Healthcare's share buyback program of at least 300 million yuan reflects management's view that the stock is undervalued, which could improve investor sentiment, Citi Research analysts say in a note. Hygeia is funding the buyback with internal cash flow, reinforcing its shift to a more cash-generative business model without straining its improving financial position, Citi says. The buyback could provide technical support and a visible demand floor for the shares in the open market over the near term, Citi adds. The combination of direct buying and improved market perception could drive the stock higher over the next 90 days. Shares last traded at HK$12.11. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","BK4588","HCSG","BK4585","LU0029874061.USD","LU0737861772.HKD","XLV","BK1583","LU0329678170.USD","LU0329678337.USD","XBI","06078","LABU","LU0128526141.USD","BK1209","BK4581","LU2488822045.USD"],"gpt_icon":0},{"id":"2591675000","title":"Sigma Healthcare May Benefit From UK's Pharmacy Store Regulation, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2591675000","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591675000?lang=en_us&edition=fundamental","pubTime":"2025-12-16 09:16","pubTimestamp":1765847799,"startTime":"0","endTime":"0","summary":"Sigma Healthcare's  Chemist Warehouse Group can potentially benefit from the United Kingdom's pharmacy location rules, according to a Monday Jefferies note.The UK's pharmacy location rules make it difficult to move licences to new locations, leading to chronic low dispensing margins, which have weakened the sector and resulted in several high-profile market exits, the note said.This may create an opportunity for a front-of-house focused operator such as Chemist Warehouse Group, provided it owns the required licences.The investment firm believes that SIG shareholders have access to \"excellent\" retail franchise exposure from Chemist Warehouse. However, Jefferies said that SIG stock is \"not cheap.\"Jefferies kept a hold rating on Sigma with a price target of AU$2.90.The company's shares rose 2% in recent Tuesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HCSG","LU0128526141.USD","XLV","BK4137","BK4581","XBI","BK7103","BK4588","LABU","LU0029874061.USD","SIG.AU","BK4585"],"gpt_icon":0},{"id":"2591672515","title":"What Prestige Consumer Healthcare (PBH)'s Buybacks and Brandes Stake Mean for Cash-Flow-Focused Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2591672515","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591672515?lang=en_us&edition=fundamental","pubTime":"2025-12-16 08:33","pubTimestamp":1765845186,"startTime":"0","endTime":"0","summary":"In the third quarter of 2025, Brandes Small Cap Value Fund disclosed a new position in Prestige Consumer Healthcare, while the company confirmed repurchasing about 4.7% of its shares since mid‑2024 for roughly US$161 million and reiterated fiscal 2026 revenue guidance that still points to a modest organic decline.\nTogether, fresh institutional buying and ongoing buybacks highlight growing confidence in Prestige’s acquisition-led model and its focus on resilient, as-needed over-the-counter...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pbh/prestige-consumer-healthcare/news/what-prestige-consumer-healthcare-pbhs-buybacks-and-brandes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pbh/prestige-consumer-healthcare/news/what-prestige-consumer-healthcare-pbhs-buybacks-and-brandes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0128526141.USD","BK4581","HCSG","LABU","LU0029874061.USD","XBI","PBH","BK7078","BK4588","PBH.AU","BK4585","BK4007","XLV","BK4137"],"gpt_icon":0},{"id":"2591620527","title":"Perennial Healthcare City Launched Adjacent to Chongqing East HSR Station, Western China's Largest HSR Hub","url":"https://stock-news.laohu8.com/highlight/detail?id=2591620527","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591620527?lang=en_us&edition=fundamental","pubTime":"2025-12-16 07:05","pubTimestamp":1765839900,"startTime":"0","endTime":"0","summary":"Establishment of new healthcare gateway inChongqing amid the 10th anniversary of the Chongqing Connectivity Initiative and as part of the 35th anniversary celebration of Singapore-China diplomatic relations;Maiden investment inChongqing marks Perennial Holdings' sixth healthcare-centric TOD, further strengthening its footprint in China. SINGAPORE, Dec. 16, 2025 /PRNewswire/ -- Perennial Holdings Private Limited yesterday launched Perennial Healthcare City, adjacent to the Chongqing East High-Speed Railway  Station . Perennial Healthcare City Chongqing, which is majority owned and led by Perennial Holdings, is jointly developed with Chongqing Transportation Development and Investment Group Co., Ltd  and China Railway Construction Group Co., Ltd . Chongqing East HSR station is the largest and only national-level HSR hub in Western China.From left to right: Mr Zhao Xiangdong, General Manager and Deputy Party Secretary of China Railway Construction Group; Mr Tan Kiat How, Singapore Senior ","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2845708/Perennial_Healthcare_City_Chongqing_Phase_1___Overview.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2845708/Perennial_Healthcare_City_Chongqing_Phase_1___Overview.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/perennial-healthcare-city-launched-adjacent-to-chongqing-east-hsr-station-western-chinas-largest-hsr-hub-302642743.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","XBI","BK4168","IE0031619046.USD","XLV","LU0128526141.USD","WRN","LABU","BK4588","HCSG","BK4585","LU0029874061.USD","HUBG","BK4581","CHCO","IE00B7SZL793.SGD","BK4211","BK4137","IE00B66KJ199.SGD","BK4131"],"gpt_icon":0},{"id":"2591624548","title":"Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2591624548","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591624548?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:05","pubTimestamp":1765832700,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., Dec.  15, 2025  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205840/0/en/Madrigal-Pharmaceuticals-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550577.SGD","LU1548497426.USD","BK4585","BK4588","LU1791710400.SGD","BK4139","LU2089284900.SGD","LU0912757837.SGD","LU0267386448.USD","LU0158827781.USD","LU2028103732.USD","BK4534","LU0106261372.USD","LU2271345857.HKD","LU1720051108.HKD","LU2023251221.USD","LU2347655156.SGD","LU1732799900.SGD","XBI","HCSG","LU0106831901.USD","MDGL","XLV","LU1989772923.USD","LU0098860793.USD","LABU","BK4127","LU2357305700.SGD","IE00BKVL7J92.USD","LU0971096721.USD","LU2089283258.USD","BK4137","LU2133065610.SGD","LU1074936037.SGD","LU0234570918.USD","LU1244550494.USD","LU0320765646.SGD","LU1668664300.SGD","LU0528227936.USD","LU0795875169.SGD","LU0029874061.USD","LU0006306889.USD","LU1244550221.USD","LU0314104364.USD","LU1162221912.USD","LU1989772840.SGD","BK4504","LU0882574139.USD","LU0225283273.USD","LU0128526141.USD"],"gpt_icon":0},{"id":"2591623441","title":"Press Release: Firstsource announces leadership changes to accelerate growth across Healthcare Payer and Provider businesses","url":"https://stock-news.laohu8.com/highlight/detail?id=2591623441","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591623441?lang=en_us&edition=fundamental","pubTime":"2025-12-16 01:02","pubTimestamp":1765818120,"startTime":"0","endTime":"0","summary":"MUMBAI, India, Dec. 15, 2025 /PRNewswire/ -- Firstsource Solutions Limited  , a leading global provider of business process management services and an RP-Sanjiv Goenka Group company, today announced the appointment of two senior leaders to head its Healthcare businesses in North America. Matthew Barlow joins as Head, Healthcare Payer business, and Scott Schrader joins as Head, Healthcare Provider business, effective December 15, 2025. Healthcare is a core growth pillar and a critical source of strategic differentiation for Firstsource. With a strong, well-diversified presence across both payer and provider segments, Firstsource brings a rare, end-to-end perspective across the healthcare value chain. As the portfolio continues to expand in both scale and complexity, the introduction of two dedicated leadership roles underscores a sharper, more deliberate focus on the distinct needs, operating dynamics, and growth opportunities within each segment.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","BK4585","BK4588","TM","HCSG","BK4581","LU0128526141.USD","BK4604","LU0029874061.USD","XLV","BK4099","BK4555","XBI","03160","LABU"],"gpt_icon":0},{"id":"2591625064","title":"Healthcare Realty Trust (HR): Valuation Check After Cantor Backs Strategy and $1 Billion Asset Sale Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2591625064","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591625064?lang=en_us&edition=fundamental","pubTime":"2025-12-16 00:16","pubTimestamp":1765815393,"startTime":"0","endTime":"0","summary":"Healthcare Realty Trust (HR) is back in focus after Cantor Fitzgerald backed its ongoing strategic overhaul, highlighting that the REIT’s planned asset sales of more than 1 billion dollars align with falling cap rates in medical office deals.\nSee our latest analysis for Healthcare Realty Trust.\nThat backdrop helps explain why, even with the latest share price at $17.18 and a softer 1 month share price return, Healthcare Realty Trust still shows a positive year to date share price return and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9621071-choice2-main-header/1585186711356","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9621071-choice2-main-header/1585186711356"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-hr/healthcare-realty-trust/news/healthcare-realty-trust-hr-valuation-check-after-cantor-back","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-hr/healthcare-realty-trust/news/healthcare-realty-trust-hr-valuation-check-after-cantor-back","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","XLV","HR","BK4581","BK4203","BK4588","BK4225","BK4585","XBI"],"gpt_icon":0},{"id":"2591471696","title":"SCWorx Continues to Expand Healthcare Data Management Network with New Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2591471696","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591471696?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:45","pubTimestamp":1765809900,"startTime":"0","endTime":"0","summary":"Middleton, MA, Dec.  15, 2025  (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX) today announced a new partner agreement with a leading healthcare supply chain partner, further strengthening its SaaS da","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205549/0/en/SCWorx-Continues-to-Expand-Healthcare-Data-Management-Network-with-New-Partnership.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128526141.USD","BK4585","BK4588","XBI","BK4137","XLV","HCSG","BK4581","LU0029874061.USD","LABU"],"gpt_icon":0},{"id":"2591723644","title":"Sector Update: Health Care Stocks Advance Pre-Bell Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2591723644","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591723644?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:16","pubTimestamp":1765808171,"startTime":"0","endTime":"0","summary":"Health care stocks were advancing pre-bell Monday, with the iShares Biotechnology ETF  up 0.7% and the State Street Health Care Select Sector SPDR ETF  advancing by 0.4%.Argenx  shares were down nearly 6% after the company said it has discontinued a phase 3 study of its therapy subcutaneously administered efgartigimod in adults with moderate to severe thyroid eye disease.Immunome  stock was up nearly 20% after the company said its global pivotal phase 3 trial evaluating varegacestat, an investigational gamma secretase inhibitor, in patients with progressing desmoid tumors met its primary endpoint of improving progression-free survival.Amphastar Pharmaceuticals  shares were up more than 2% after the company said the US Food and Drug Administration approved the abbreviated New Drug Application for its teriparatide injection as a treatment for osteoporosis.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","IE00BJT1NW94.SGD","LU1983260115.SGD","LU0320765992.SGD","LU0889565916.HKD","BK4139","IE0009355771.USD","BK4563","BK4585","IE0034235188.USD","IMNM","XBI","LU2324357040.USD","IE00BFTCPJ56.SGD","XLV","AMPH","LU0109394709.USD","IE00B4R5TH58.HKD","IBB","BK4588","BK4557","BK4007","LABU","IE0002141913.USD","BK4505","ARGX","IE00BJJMRZ35.SGD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2591494896","title":"Hygeia Healthcare Eyes 300 Million Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2591494896","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591494896?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:06","pubTimestamp":1765804008,"startTime":"0","endTime":"0","summary":"Hygeia Healthcare (HKG:6078) intends to buy back up to 300 million of shares from the open market from time to time, a Monday Hong Kong bourse filing said.Under its current repurchase mandate, the healthcare firm is allowed to buy back up to 61.8 million, or 10%, of its issued shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","XBI","HCSG","LU0737861772.HKD","LU2488822045.USD","LU0128526141.USD","BK4137","BK4585","BK4588","LU0329678337.USD","LU0329678170.USD","BK1209","XLV","LU0029874061.USD","06078","BK1583","LABU"],"gpt_icon":0},{"id":"2591649410","title":"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649410","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649410?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803600,"startTime":"0","endTime":"0","summary":"BOSTON, Dec.  15, 2025  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205352/0/en/Bicara-Therapeutics-to-Present-at-the-J-P-Morgan-2026-Annual-Healthcare-Conference-on-Monday-January-12.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","LU0158827781.USD","LU0882574139.USD","LU2133065610.SGD","LU1720051108.HKD","LU0267386448.USD","LU1548497426.USD","LU2028103732.USD","IE00BZ1G4Q59.USD","LU1791710582.SGD","LU1720051017.SGD","LU1989772923.USD","LU1244550221.USD","IE00BKVL7J92.USD","LU0006306889.USD","LU1989772840.SGD","LU1791710400.SGD","LU0234570918.USD","LU0098860793.USD","BCAX","LU1732799900.SGD","BK4516","BK4127","LU0106831901.USD","XLV","LU0971096721.USD","LU1732800096.USD","LU2357305700.SGD","XBI","LU2089283258.USD","LU0128526141.USD","LU2023251221.USD","LU1363072403.SGD","LU2111349929.HKD","LU0557290698.USD","BK4585","LU0314104364.USD","LU1244550494.USD","LU0528227936.USD","LU2089284900.SGD","BK4137","BK4504","LU0029874061.USD","LU1668664300.SGD","LU0795875086.SGD","LU0158827948.USD","BK4588","BK4581","HCSG","LU0795875169.SGD"],"gpt_icon":0},{"id":"2591644592","title":"Reassessing Molina Healthcare (MOH): Is the Recent Share Price Rebound Enough to Shift Its Valuation?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644592","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591644592?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:16","pubTimestamp":1765797367,"startTime":"0","endTime":"0","summary":"Why Molina Healthcare Is Back on Investors' Radar\nMolina Healthcare (MOH) has quietly staged a comeback, with shares up about 9% over the past week and more than 22% this month, even as the past 3 months remain slightly negative.\nSee our latest analysis for Molina Healthcare.\nThat sharp 22.5% 1 month share price return looks more like a relief rally than a full turnaround, given the 41.3% year to date share price decline and similarly weak longer term total shareholder returns.\nIf Molina’s...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6034000-choice2-main-header/1585187286151","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6034000-choice2-main-header/1585187286151"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-moh/molina-healthcare/news/reassessing-molina-healthcare-moh-is-the-recent-share-price","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-moh/molina-healthcare/news/reassessing-molina-healthcare-moh-is-the-recent-share-price","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4532","XLV","SG9999014039.USD","LABU","BK4154","BK7104","SG9999014021.USD","BK4585","SG9999014013.SGD","BK4588","MOH.AU","XBI","BK4581","MOH","SG9999014005.SGD"],"gpt_icon":0},{"id":"2591697751","title":"Manulife and Bupa Sign MoU for Strategic Collaboration in Hong Kong to Create a More Robust, Integrated Healthcare Network Offering Customers Greater Access and Choice","url":"https://stock-news.laohu8.com/highlight/detail?id=2591697751","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591697751?lang=en_us&edition=fundamental","pubTime":"2025-12-15 13:45","pubTimestamp":1765777500,"startTime":"0","endTime":"0","summary":"HONG KONG, Dec. 15, 2025 /PRNewswire/ -- Manulife  Limited and Bupa International Limited arepleased to announce today the signing of a Memorandum of Understanding , intended to establish a strategic collaboration in Hong Kong that will provide customers with greater convenience and flexibility in managing their health.Manulife and Bupa have signed an MoU for strategic collaboration in Hong Kong to create a more robust, integrated healthcare network offering customers greater access and choice. Pictured at the signing ceremony are Patrick Graham, CEO of Manulife Hong Kong and Macau , and Fiona Harris, Managing Director of Bupa Hong Kong .Fiona Harris, Managing Director of Bupa Hong Kong, said, \"Collaborations aremore important than ever as we work together to deliver the connected healthcare ecosystem that enables each consumer to achieve their best health outcome. By joining forces, we can reach more of the people of Hong Kong, introducing new innovations and creating more opportun","market":"us","thumbnail":"https://mma.prnewswire.com/media/2845172/Manulife___Bupa_MoU_ceremony_photo_1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2845172/Manulife___Bupa_MoU_ceremony_photo_1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/manulife-and-bupa-sign-mou-for-strategic-collaboration-in-hong-kong-to-create-a-more-robust-integrated-healthcare-network-offering-customers-greater-access-and-choice-302641904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","XBI","BK4142","MFC","BK4585","CUBI","BK4137","HCSG","BK4588","LU0029874061.USD","LU0128526141.USD","BK4162","CHH","LABU","XLV","BK4581"],"gpt_icon":0},{"id":"2591467692","title":"Two Chinese Healthcare Firms Eye Hong Kong IPOs Amid Biopharma Fundraising Boom","url":"https://stock-news.laohu8.com/highlight/detail?id=2591467692","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591467692?lang=en_us&edition=fundamental","pubTime":"2025-12-15 12:52","pubTimestamp":1765774320,"startTime":"0","endTime":"0","summary":"Two Chinese healthcare companies have started taking orders for their initial public offerings in Hong Kong, joining a long list of Chinese biomedical companies seeking to raise funds in the Asian financial hub this year.QingSong Health Corporation wants to raise up to 601.9 million Hong Kong dollars, equivalent to US$77.3 million, by issuing 26.5 million shares at HK$22.68 each. Hanx Biopharmaceuticals wants to raise HK$586.3 million by issuing 18.3 million shares at HK$32.00 each.Both offerings are scheduled to close on Thursday, with shares set to start trading on Dec. 23.According to filings to the Hong Kong exchange Monday, QingSong plans to use the net proceeds to increase its brand visibility and enhance user engagement, boost its medical research, enhance its technology capabilities in AI and big data and expansion into overseas markets. Hanx said it will use the funds raised on the research and development of its various treatments and on business development activities.The Be","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0029874061.USD","LU0128526141.USD","BK4137","XBI","LABU","XLV","HCSG","BK4588","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}